This is a Validated Antibody Database (VAD) review about mouse Nfat5, based on 5 published articles (read how Labome selects the articles), using Nfat5 antibody in all methods. It is aimed to help Labome visitors find the most suited Nfat5 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Nfat5 synonym: AI225870; B130038B15Rik; CAG-8; CAG80; NFATL1; OREBP; TonEBP; mKIAA0827; nfatz; nuclear factor of activated T-cells 5; T-cell transcription factor NFAT5; rel domain-containing transcription factor NFAT5; tonicity-responsive enhancer binding protein
Abcam
rabbit polyclonal |
| Abcam Nfat5 antibody (Abcam, AB3446) was used in immunohistochemistry on human samples . PLoS ONE (2013) ncbi |
rabbit polyclonal |
| Abcam Nfat5 antibody (Abcam, ab3446) was used in immunocytochemistry on human samples and in western blot on human samples at 1:2000. J Lipid Res (2013) ncbi |
Novus Biologicals
rabbit polyclonal |
| Novus Biologicals Nfat5 antibody (Novus Biologicals, NB120-3446) was used in western blot on mouse samples at 1:1000 (fig 8c). Sci Rep (2017) ncbi |
Invitrogen
rabbit polyclonal |
| In order to analyze organotropic metasistasis and tumour exosome integrins, Invitrogen Nfat5 antibody (Thermo Scientific, PA1-023) was used in western blot on human samples at 1:100 (fig s7). Nature (2015) ncbi |
MilliporeSigma
rabbit polyclonal |
| MilliporeSigma Nfat5 antibody (SIGMA ALDRICH, SAB4504718) was used in western blot on human samples at 1:200 (fig 2). Oncol Lett (2016) ncbi |
Articles Reviewed
- Amara S, Alotaibi D, Tiriveedhi V. NFAT5/STAT3 interaction mediates synergism of high salt with IL-17 towards induction of VEGF-A expression in breast cancer cells. Oncol Lett. 2016;12:933-943 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments